Assist Prof Dr. Juan Yakisich – Cancer Cell Biology – Best Researcher Award

Posted on 02/03/202402/03/2024 by Pencis

Assist Prof Dr. Juan Yakisich - Cancer Cell Biology - Best Researcher Award

Hampton University - United States

AUTHOR PROFILE

EARLY ACADEMIC PURSUITS

Juan Sebastian Yakisich, MD, PhD, pursued an interdisciplinary biomedical research path, obtaining his doctoral education at the esteemed Karolinska Institute in Europe, one of the largest and most prestigious medical universities. His early academic pursuits laid the foundation for his expertise in cell & molecular biology, cancer biology & molecular oncology, and pharmacology.

PROFESSIONAL ENDEAVORS

Following his doctoral education, Dr. Yakisich undertook postdoctoral training at the Department of Molecular and Cellular Medicine, Texas A&M University, College Station, TX. His professional journey also included a highly competitive and prestigious research grant from the Swedish Research Council, leading to four additional years as a project leader at the Department of Clinical Neuroscience, Karolinska Institute.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER CELL BIOLOGY

Dr. Yakisich possesses a comprehensive background in cancer cell biology and pharmacology, specializing in cellular and molecular biology, anticancer drug screening, and cancer stem cell biology. His significant contributions include the development of a groundbreaking cancer stem cell model (The stemness phenotype model) applicable to various cancer types, with substantial clinical implications. Additionally, he pioneered effective strategies for anticancer drug screening, addressing limitations in existing programs.

IMPACT AND INFLUENCE

As an oncology researcher, Dr. Yakisich has made a substantial impact, contributing to the understanding and treatment of various cancers, including brain tumors, cervical, lung, and breast cancers. His work has not only shaped research directions but has practical applications in clinical settings, improving the screening of oncology markers and enhancing drug delivery into cancer cells.

ACADEMIC CITES

Dr. Yakisich's academic achievements are reflected in his publication record, including over 60 peer-reviewed original articles and reviews in international leading journals. He has served as a grant and postdoctoral fellowship reviewer for NASA and held editorial and associate board memberships in international peer-reviewed journals such as Frontiers in Pharmacology.

LEGACY AND FUTURE CONTRIBUTIONS HIGHLIGHT

In his tenure at Hampton University, Dr. Yakisich has continued to contribute significantly, publishing over twenty-five peer-reviewed articles and three book chapters. His commitment to education is evident through mentoring and training Master's, PhD, undergraduate, and high school students in multiple countries. Dr. Yakisich emphasizes a commitment to mentor and train underrepresented minorities in basic and translational research, leaving a lasting legacy of diversity and inclusion.

FUTURE CONTRIBUTIONS

Looking ahead, Dr. Yakisich is actively engaged in the development of aptamer-based biomedical tools for identifying oncology markers, pathogen detection and elimination, and drug delivery into cancer cells. His dedication to mentoring and training underscores a commitment to advancing scientific knowledge and fostering the next generation of researchers, ensuring a continued impact on the field of biomedical research.

NOTABLE PUBLICATIONS

A short post reattachment ultra-sensitive window of time in human cancer cells as therapeutic target of prolonged low dose administration of specific compounds. 2024

Two-Step Preparation of Protein-Decorated Biohybrid Quantum Dot Nanoparticles for Cellular Uptake. 2023

Phenotypic Characterization of 2D and 3D Prostate Cancer Cell Systems Using Electrical Impedance Spectroscopy. 2023

Downregulation of DKK-1 and Upregulation of B - Catenin in Cancer Floating Spheroids is Associated with Chemoresistance to Wnt Signaling Pathway Inhibitors. 2022

Translational Gap in Lung Cancer Research. 2022

Dr. Durre Nayab – Cancer Research – Best Researcher Award

Posted on 27/02/202428/02/2024 by Pencis

Dr. Durre Nayab - Cancer Research - Best Researcher Award

Technische Universitat Dresden - Germany

AUTHOR PROFILE

Google Scholar

EARLY ACADEMIC PURSUITS:

Durr-e-Nayab's academic journey began with a Bachelor's degree in Computer Systems Engineering from the University of Engineering and Technology, Peshawar, Pakistan, followed by a Master's in Computer Systems Engineering from the same institution. Later, she achieved a Ph.D. in Electrical Engineering from the University of Engineering and Technology, Peshawar, with a research focus on Adaptive Expanding Ring Search Based Per Hop Routing Rendition in Mobile Ad Hoc Networks (MANETs) using Machine Learning.

PROFESSIONAL ENDEAVORS:

Nayab has accumulated 11 years of teaching experience and 6 years of research experience. She has held various positions, including Lecturer & Batch Advisor at the University of Engineering and Technology, Peshawar, and Research Assistant at the Center for Intelligent Systems and Networks Research. Additionally, she has served as a Lecturer in Computer Science at City University of Science and Technology and Institute of Business and Management Sciences.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER RESEARCH

Her contributions extend to research projects, including a significant role as a Research Assistant in R & D Funded Projects at the Center for Intelligent Systems and Networks Research. Notable projects involve secure and intelligent transportation systems, secure billing frameworks, traffic pattern analysis, and autonomous situation-based alerts using wireless sensor networks.

IMPACT AND INFLUENCE:

Dr. Nayab's impact is evident through her contributions to projects funded by ICT R & D, Ministry of IT Pakistan, addressing critical issues such as congestion control, electricity theft, and traffic patterns in Pakistan. Her role as a Co-PI at the National Center for Artificial Intelligence showcases her influence in shaping intelligent systems design in Pakistan.

ACADEMIC CITES:

Dr. Nayab's research has made a substantial impact, with publications in reputable journals, including "Applied Computational Intelligence and Soft Computing," "Annals of Telecommunication," and "Computers, Materials & Continua."

LEGACY AND FUTURE CONTRIBUTIONS:

Dr. Nayab's legacy is marked by her dedication to research and education, particularly in the fields of Mobile Ad Hoc Networks, Machine Learning, and Artificial Intelligence. Her future contributions are anticipated in her role as a Post-Doctoral Researcher at TU Dresden, focusing on Transport Modeling, Cancer Research and Simulation.

NOTABLE PUBLICATIONS

Performance Augmentation of Base Classifiers Using Adaptive Boosting Framework for Medical Datasets. 2023

Effects of dataset attacks on machine learning models in E-health. 2023

SP-DSTS-MIMO Scheme aided H.266 for reliable high data-rate mobile video-communication. 2023

Data Augmentation and Random Multi-Model Deep Learning for Data Classification. 2022

Sparse Crowd Flow Analysis of Tawaaf of Kaaba during the COVID-19 Pandemic. 2022

Prof. Rami Nassir – Cancer Genetics – Best Researcher Award

Posted on 16/02/202416/02/2024 by Pencis

Prof. Rami Nassir - Cancer Genetics - Best Researcher Award

Pathology - School of Medicine - Umm AlQura University - Saudi Arabia

AUTHOR PROFILE

Scopus

Orcid

Google Scholar

EARLY ACADEMIC PURSUITS:

Rami M. Nassir, Ph.D., embarked on his academic journey at the University of California, Davis, focusing on Comparative Pathology with a major in Human Genetics. His early academic pursuits set the stage for a distinguished career at the intersection of genetics, pathology, and complex diseases.

PROFESSIONAL ENDEAVORS:

Nassir has seamlessly integrated academia, research, and clinical practice. Currently serving as a Professor (since July 2022) at the School of Medicine, Umm Al-Qura University, he is actively engaged in providing lectures across various pathology courses, supervising laboratory research, and contributing to small clinical research projects.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS

Rami M. Nassir's research focus spans diverse areas, including whole-genome sequencing, molecular diagnostics,cancer genetics and clinical applications in genomic medicine. His significant contributions to various sequencing platforms and meta-analyses underscore his dedication to advancing genetic research methodologies.

IMPACT AND INFLUENCE:

Nassir's impact extends beyond academia into clinical practice. His involvement in diagnosing rare genetic diseases, implementing genomic medicine in diagnostic centers, and contributing to IVF procedures demonstrates the practical application of his research.

ACADEMIC CITES:

Being a member of prestigious genetic and medical societies such as the American Society of Human Genetics and the Saudi Society for Genomics and Molecular Oncology reflects Nassir's recognition in the academic community.

LEGACY AND FUTURE CONTRIBUTIONS:

Nassir's legacy lies in his extensive research accomplishments, including his work in next-generation sequencing, meta-analyses, and population stratifications. His commitment to advancing research methodologies positions him as a trailblazer in the field.

RESEARCH ACCOMPLISHMENTS:

His proficiency in various genetic analysis techniques, from SNP genotyping to statistical analysis, highlights Nassir's comprehensive skill set and its application in contributing to major studies.

NOTABLE PUBLICATIONS

Racial and Ethnic Differences in Self-Reported COVID-19 Exposure Risks, Concerns, and Behaviors Among Diverse Participants in the Women's Health Initiative Study. 2023

Genetic control of mRNA splicing as a potential mechanism for incomplete penetrance of rare coding variants. 2023

A Genetic Locus within the FMN1/GREM1 Gene Region Interacts with Body Mass Index in Colorectal Cancer Risk. 2023

Race and Ethnicity and Fracture Prediction among Younger Postmenopausal Women in the Women's Health Initiative Study. 2023

Associations of maternal preterm birth with subsequent risk for type 2 diabetes in women from the women's health initiative. 2023

Prof. Wenhao Ouyang – Tumor Immunology – Best Researcher Award

Posted on 15/02/202415/02/2024 by Pencis

Prof. Wenhao Ouyang - Tumor Immunology - Best Researcher Award

Sun Yat-Sen Memorial Hospital - China

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS:

Wenhao Ouyang commenced his academic journey at Sun Yat-sen University, delving into the field of Medical Oncology. His early academic pursuits laid the foundation for a career marked by dedication to advancing cancer research and treatment.

PROFESSIONAL ENDEAVORS:

As a Physician and Ph.D. Candidate at Sun Yat-sen Memorial Hospital, Wenhao Ouyang's professional endeavors center around tumor big data, artificial intelligence research, tumor immunology, and immunotherapy research. His dual role as both a clinician and researcher highlights his commitment to bridging the gap between clinical practice and cutting-edge research.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY

Wenhao Ouyang has made substantial contributions to the field through his research, focusing on tumor big data, artificial intelligence, and tumor immunology. His published articles in esteemed journals showcase the depth and breadth of his research, with a focus on prognostic factors, immunotherapy response, and the tumor microenvironment.

IMPACT AND INFLUENCE:

Ouyang's impact is evident through his published articles, each addressing critical aspects of cancer research. His work, such as developing prognostic risk scores and identifying immune-inflammation signatures, reflects his influence on shaping the understanding of cancer prognosis and treatment response.

ACADEMIC CITES:

Being a reviewer for Frontiers in Immunology underscores Wenhao Ouyang's standing in the academic community. Reviewing articles in this reputable journal demonstrates his expertise and recognition within the field, contributing to the advancement of scientific knowledge.

LEGACY AND FUTURE CONTRIBUTIONS:

Wenhao Ouyang's legacy is unfolding through a substantial body of work that has already left a mark on cancer research. His role as a major participant in the selection of articles for the 2023 ESMO Asia poster highlights his commitment to sharing knowledge and advancing the field on a global scale.

HIGHLIGHT OF FUTURE CONTRIBUTIONS:

Looking forward, Ouyang's involvement in groundbreaking projects, such as multimodal data fusion for improved risk stratification of breast cancer, signals a trajectory of continued impact. His role in precision neoadjuvant chemotherapy and distinguishing tumor immunotyping heterogeneity positions him as a key figure in shaping the future of cancer research and treatment.

NOTABLE PUBLICATION

Immune gene patterns and characterization of the tumor immune microenvironment associated with cancer immunotherapy efficacy. 2023 (1)

Machine learning radiomics of magnetic resonance imaging predicts recurrence-free survival after surgery and correlation of LncRNAs in patients with breast cancer: a multicenter cohort study. 2023 (1)

Identification of a tumor immune-inflammation signature predicting prognosis and immune status in breast cancer. 2023

A Comprehensive Analysis of Programmed Cell Death-Associated Genes for Tumor Microenvironment Evaluation Promotes Precise Immunotherapy in Patients with Lung Adenocarcinoma. 2023

Prognosis and Immunotherapy Response With a Novel Golgi Apparatus Signature-Based Formula in Lung Adenocarcinoma. 2022 (2)

A Prognostic Risk Score Based on Hypoxia-, Immunity-, and Epithelialto-Mesenchymal Transition-Related Genes for the Prognosis and Immunotherapy Response of Lung Adenocarcinoma. 2022 (19)

Assoc Prof Dr. RAFİYE CİFTCİLER – Targeted Cancer Therapy – Best Review Article Award

Posted on 15/02/202415/02/2024 by Pencis

Assoc Prof Dr. RAFİYE CİFTCİLER - Targeted Cancer Therapy - Best Review Article Award

SELCUK UNIVERSITY FACULTY OF MEDICINE DEPARTMENT OF HEMATOLOGY -Turkey

AUTHOR PROFILE

Scopus

Orcid

Google Scholar

EARLY ACADEMIC PURSUITS:

Rafıye Ciftciler embarked on her academic journey with a strong foundation in medicine and a focus on hematology. She pursued her Medical School education at Hacettepe University Faculty of Medicine, where she laid the groundwork for her future contributions to the field.

PROFESSIONAL ENDEAVORS:

Following her medical education, Rafıye Ciftciler delved into Internal Medicine at Gazi University Faculty of Medicine, broadening her clinical expertise. Subsequently, she specialized in Hematology at Hacettepe University Faculty of Medicine, honing her skills in the intricate field of blood disorders.

CONTRIBUTIONS AND RESEARCH FOCUS ON TARGETED CANCER THERAPY

Rafıye Ciftciler has significantly contributed to the science of hematology, with approximately 100 publications to her name. Her research encompasses a diverse range of topics within hematology, showcasing her dedication to advancing knowledge in the field.

IMPACT AND INFLUENCE:

Her impact extends beyond publications, as evidenced by her accolades. The Young Researcher Award from the Turkish Society of Hematology at the 44th National Hematology Congress and the Oral Presentation Award at the 3rd National Blood and Bone Marrow Transplant Congress underscore her influence in the academic and scientific community.

ACADEMIC CITES:

Rafıye Ciftciler's work has likely garnered attention within the academic community, reflected in her certifications from esteemed organizations like the European Hematology Association and the Turkish Hematology Association. These certifications affirm her proficiency and recognition in the broader scientific arena.

LEGACY AND FUTURE CONTRIBUTIONS:

As an Associate Professor in the Department of Hematology at Selcuk University Faculty of Medicine, Rafıye Ciftciler has already established a commendable legacy. Her continuous contributions to the science of hematology and her role in shaping the next generation of medical professionals mark her as a key figure in the field.

HIGHLIGHT OF FUTURE CONTRIBUTIONS:

Looking ahead, Rafıye Ciftciler's future contributions are anticipated to further enrich the field of Targeted Cancer Therapy. Whether through groundbreaking research, mentorship, or educational initiatives, her commitment to advancing knowledge and improving patient care is poised to leave a lasting impact on the discipline.

NOTABLE PUBLICATIONS

Efficacy and Safety of Immune Checkpoint Inhibitors in Hematologic Malignancies. 2024

The Effect of Obesity and Body Mass Index on Hematologic Malignancies. 2023

Hereditary thrombocytopenia with familial novel mutation in MYH9 gene: A familial case report. 2023

Immune Thrombotic Thrombocytopenic Purpura in Elderly Patients: The Roles of PLASMIC and French Scores. 2023

Dr. Fatemeh Kanaani Nejad – Breast Cancer Screening – Best Researcher Award

Posted on 14/02/202415/02/2024 by Pencis

Dr. Fatemeh Kanaani Nejad - Breast Cancer Screening - Best Researcher Award

Anesthesiology and Critical Care Research Center - Iran

Author Profile

Google Scholar

EARLY ACADEMIC PURSUITS:

Fatemeh Kanaani Nejad was an academically driven individual from early on, demonstrating her commitment to education during her high school years at Farzanegan High School in Shiraz, Iran (2011-2014). Her consistent dedication and performance laid the foundation for her subsequent academic journey.

PROFESSIONAL ENDEAVORS:

After completing high school, Fatemeh pursued her Medical Doctor (MD) degree at Isfahan University of Medical Sciences, Isfahan, Iran, from February to July 2015. She continued her medical education at Shiraz University of Medical Sciences, Shiraz, Iran, graduating in February 2022. Following her academic achievements, she embarked on a postdoctoral research position at the Anesthesiology and Critical Care Research Center, Shiraz University of Medical Sciences, starting in September 2022.

CONTRIBUTIONS AND RESEARCH FOCUS ON BREAST CANCER SCREENING

Fatemeh actively engaged in various workshops and certifications, showcasing her commitment to expanding her skill set. Notably, she participated in workshops such as Search, Study Design, and Proposal Writing, as well as Python training. Her research focus, primarily in the field of Anesthesiology and Critical Care, is evident in her contributions to poster presentations for the European Society of Radiology (ECR 2023). These contributions cover topics ranging from targeted ultrasound of the breast to the application of shear wave elastography in breast cancer screening.

IMPACT AND INFLUENCE:

Fatemeh's impact extends beyond her academic pursuits. Her poster presentation on "Anti-Inflammatory Therapy in Hair Loss Treatment" at The Second International Conference on Holly Prophet Mohammad’s Tradition reflects her engagement with interdisciplinary topics and potential implications for medical treatments.

ACADEMIC CITES:

While specific citation numbers are not provided, Fatemeh's work is disseminated through DOI-linked poster presentations. This suggests that her research is accessible and has the potential for citation within the academic community.

LEGACY AND FUTURE CONTRIBUTIONS:

Fatemeh's legacy is marked by her achievements as the first-ranked student in Farzanegan high school and the second-ranked student among Isfahan University of Medical Sciences students in 2015. Her mentorship role in the Medical Physics Research Center and continued contributions to conferences indicate a promising future of further academic and professional accomplishments.

NOTABLE PUBLICATIONS

Dr. Linxi Zhu – Cancer Genetics – Best Researcher Award

Posted on 12/02/202414/02/2024 by Pencis

Dr. Linxi Zhu - Cancer Genetics - Best Researcher Award

Nanjing Drum Tower Hospital - China

Author Profile

Scopus

EARLY ACADEMIC PURSUITS:

Linxi Zhu commenced her academic journey at Nanjing University, where she pursued a Bachelor's degree from July 2015 to June 2020. Following her undergraduate studies, she continued her academic pursuit at the same institution, earning a Master's degree from July 2020 to June 2021. Linxi Zhu then advanced further in her educational journey, undertaking a Ph.D. program at Nanjing University from July 2021 to June 2023.

PROFESSIONAL ENDEAVORS:

Since September 2023, Linxi Zhu has been serving as a Surgeon at Nanjing Drum Tower Hospital, marking a significant transition from academic pursuits to practical application in the field of surgery.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER GENETICS :

Linxi Zhu's research has made notable contributions to the field of cancer genetics. Notably, her work titled "Loss of Claudin-1 incurred by DNMT aberration promotes pancreatic cancer progression" (published in Cancer Lett., 2024) sheds light on the molecular mechanisms underlying pancreatic cancer progression. Additionally, she has contributed to the development and validation of a nomogram for predicting post-operative abdominal infection in patients undergoing pancreaticoduodenectomy, as well as exploring the role of preoperative biliary drainage in postoperative outcomes after pancreaticoduodenectomy.

IMPACT AND INFLUENCE:

Zhu's research impact extends beyond pancreatic cancer, with contributions to the field of intrahepatic cholangiocarcinoma. Her collaborative work on high endothelial venule as a prognostic immune-related biomarker in patients with resected intrahepatic cholangiocarcinoma (published in Cell Prolif., 2023) underscores her diverse research interests.

ACADEMIC CITES:

Linxi Zhu has published in reputable journals, evident from her publications in Cancer Lett., Clin Chim Acta, Gland Surg, Cell Prolif., and Front Oncol. The citations received for her work demonstrate its scholarly significance and recognition within the academic community.

LEGACY AND FUTURE CONTRIBUTIONS:

Zhu's legacy lies in her comprehensive understanding of pancreatic cancer and related surgical interventions. Her research on individualized chemotherapy combined with sequential immunotherapy based on BRCA1 mRNA expression level in unresectable pancreatic cancer showcases innovative approaches. Looking forward, Linxi Zhu is poised to contribute further to the field, leaving a lasting impact on surgical and oncological research.

NOTABLE PUBLICATIONS

Assoc Prof Dr. Mario I. Vega – Tumor Immunology – Best Researcher Award

Posted on 24/01/202414/02/2024 by Pencis

Assoc Prof Dr. Mario I. Vega - Tumor Immunology - Best Researcher Award

University of California Los Angeles - United States

Author Profile

Orcid

EARLY ACADEMIC PURSUITS:

Mario I. Vega initiated his academic journey at the Universidad Autónoma Metropolitana Campus Xochimilco, Mexico City, serving as a Research Technical Assistant in the Department of Leptospirosis Human Research from 1991 to 1992. He continued his research roles at the Hospital Infantil de Mexico "Federico Gomez" and the Instituto Mexicano del Seguro Social (IMSS) with a focus on immunology and infectious diseases.

PROFESSIONAL ENDEAVORS:

Mario I. Vega's professional trajectory includes positions at prestigious institutions, such as UCLA AIDS Institute and IMSS, where he advanced from Assistant Researcher to Professor in the field of tumor immunology and infectious diseases. Notably, he has been associated with UCLA Medical Center, Jonsson Comprehensive Cancer Center, contributing as Staff Associate Researcher in the Clinical Nutrition Division.

CONTRIBUTIONS AND RESEARCH FOCUS ON TUMOR IMMUNOLOGY:

Dr. Vega's research contributions span diverse areas, from rituximab inhibition of p38 MAPK activity in B NHL to extensive work in immunology, cancer, and infectious diseases. His research expertise includes molecular biology, DNA replication, PCR, and immunotherapy. Serving on various review committees and editorial boards, he has actively contributed to scientific evaluations and publications.

IMPACT AND INFLUENCE:

Dr. Mario I. Vega's impact is evident through numerous honors and awards, such as the American Society of Hematology (ASH) Travel Award in 2004 and consecutive Fogarty fellowships at UCLA from 2004 to 2013. His recognition extends to national and international awards in pediatric research, biomedical research, and contributions to scientific journals.

ACADEMIC CITES:

Dr. Vega has left a mark on academia with memberships in esteemed organizations like ASH, AACR, and AAI. His participation in teaching activities, including courses on molecular biology, immunology, and cancer, demonstrates his commitment to knowledge dissemination.

LEGACY AND FUTURE CONTRIBUTIONS:

This overview highlights Dr. Mario I. Vega's academic and professional journey, his substantial contributions to medical research, and the potential impact of his continued work on the fields of immunology and oncology.

Notable Publications

Regulation of Krüppel-Like Factor 4 (KLF4) expression through the transcription factor Yin-Yang 1 (YY1) in non-Hodgkin B-cell lymphoma.2019

Role of MicroRNA-7 (MiR-7) in Cancer Physiopathology.2022

Roles and Regulation of BCL-xL in Hematological Malignancies.2022

Prof Dr.Isabel Heidegger – Oncology and Precision Medicine – Best Researcher Award

Posted on 18/01/202414/02/2024 by Pencis

Prof Dr.Isabel Heidegger - Oncology and Precision Medicine - Best Researcher Award

Medizinische Universität Innsbruck - Austria

AUTHOR PROILE

Scopus

EARLY ACADEMIC PURSUITS:

Isabel Heidegger commenced her academic journey with a strong foundation in the field of medicine. She pursued her early education with a focus on urology, setting the stage for her future contributions to the medical community.

PROFESSIONAL ENDEAVORS:

Isabel Heidegger's professional journey has been marked by significant achievements. Joining the Department of Urology at the Medical University Innsbruck in 1984, she steadily progressed in her career. Currently holding the distinguished position of Professor of Translational Prostate Cancer Therapy and Deputy Director of the Department of Urology, her leadership is evident in both clinical and research aspects.

CONTRIBUTIONS AND RESEARCH FOCUS ON ONCOLOGY AND PRECISION MEDICINE

Heidegger has made substantial contributions to the field of oncology and precision medicine, with a primary focus on translational prostate cancer therapy. Her work encompasses both basic-translational and clinical science. Her dedication to prostate cancer research extends to conservative and surgical treatment modalities.

IMPACT AND INFLUENCE:

As a physician-scientist specializing in prostate cancer, Heidegger's impact reverberates through her extensive research and clinical endeavors. Her commitment to advancing knowledge and improving patient outcomes has positioned her as a key influencer in the domain of urology.

ACADEMIC CITES:

Isabel Heidegger's work has garnered recognition in academic circles, evident in her citations and contributions to scholarly publications. Her research findings and clinical insights have contributed to the academic discourse in urology and prostate cancer treatment.

LEGACY AND FUTURE CONTRIBUTIONS:

Heidegger's legacy is shaped by her tireless pursuit of excellence in prostate cancer research and therapy. Her ongoing contributions lay the groundwork for future advancements in urology. The impact of her work is poised to endure, leaving a lasting legacy in the realm of translational medicine and prostate cancer treatment.

NOTABLE PUBLICATION

STAT3/LKB1 controls metastatic prostate cancer by regulating mTORC1/CREB pathway.2023

Real-world comparison of Docetaxel versus new hormonal agents in combination with androgen-deprivation therapy in metastatic hormone-sensitive prostate cancer descrying PSA Nadir ≤ 0.05 ng/ml as marker for treatment response.2022

Mr.Manoj Kumar Srinivasan – Cancer Cell Biology – Best Researcher Award

Posted on 12/01/202414/02/2024 by Pencis

Mr.Manoj Kumar Srinivasan - Cancer Cell Biology - Best Researcher Award

Annamalai University - Chidambaram

AUTHOR PROFILE

Scopus

EARLY ACADEMIC PURSUITS

Manojkumar Srinivasan embarked on his academic journey with a Master of Science in Biotechnology at Annamalai University, India, from July 2016 to May 2021. His commitment and dedication during this period were reflected in his impressive Cumulative Grade Point (CGP) of 80.03%. As part of his academic pursuits, he also pursued a Diploma in Food and Nutrition from June 2020 to May 2021, further diversifying his expertise.

PROFESSIONAL ENDEAVORS

In March 2022, Manojkumar stepped into the realm of research as a Project Fellow in the Cancer Biology Lab at the Department of Biochemistry & Biotechnology, Annamalai University, India. In this role, he is actively engaged in a project titled "Synthesis of pH-sensitive Carvacrol Zinc Oxide Quantum Dots (CVC-ZnO QDs) and evaluation of its anti-neoplastic and antimetastatic effect in vitro and in vivo." This experience has allowed him to apply his academic knowledge to real-world scientific investigations.

CONTRIBUTIONS AND RESEARCH FOCUS ON CANCER CELL BIOLOGY

Manojkumar's Master's thesis, conducted at the Department of Biotechnology, Annamalai University, focused on the "Proximate analysis and glycemic index of Manipuri black rice." This research not only showcased his analytical skills but also contributed valuable insights to the understanding of nutritional aspects of Manipuri black rice.

IMPACT AND INFLUENCE

While pursuing his Ph.D. in Biotechnology at Annamalai University since January 2022, Manojkumar has been immersed in research endeavors, demonstrating his commitment to advancing knowledge in the field. His work in cancer cell biology, particularly in the synthesis and evaluation of novel quantum dots, holds promise for potential applications in anti-neoplastic and antimetastatic interventions.

ACADEMIC CITATIONS

Manojkumar's academic journey is marked by rigorous exploration and study, laying the foundation for his contributions to the scientific community. His work may have garnered citations and acknowledgments within academic circles, reflecting the impact of his research on the broader scientific landscape.

LEGACY AND FUTURE CONTRIBUTIONS

As a Ph.D. graduate in Biotechnology with a focus on cancer biology, Manojkumar aspires to leave a lasting legacy through his research contributions. His dedication to life sciences and commitment to ongoing projects suggest a promising future where he continues to make meaningful contributions to the scientific understanding of cancer and related fields.

NOTABLE PUBLICATIONS

Ameliorated antimicrobial, antioxidant, and anticancer properties by Plectranthus vettiveroides root extract-mediated green synthesis of chitosan nanoparticles.2023

Ameliorative Effect of Rutin against Zirconium Oxide (ZrO2) Nanoparticle induced Behavioural, Biochemical and Tissue Morphological Changes in Danio rerio.2023